Oxford PharmaGenesis Revenue and Competitors

Claim your profile

Oxford, UK

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Oxford PharmaGenesis's estimated annual revenue is currently $106.9M per year.(i)
  • Oxford PharmaGenesis's estimated revenue per employee is $201,000

Employee Data

  • Oxford PharmaGenesis has 532 Employees.(i)
  • Oxford PharmaGenesis grew their employee count by 15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$17.7M88-5%N/AN/A
#2
$16.1MN/AN/AN/A
#3
$94.9M472-14%N/AN/A
#4
$350.1M17429%N/AN/A
#5
$237.4M118134%N/AN/A
#6
$10.1M50-18%N/AN/A
#7
$33.2M165-4%N/AN/A
#8
$21.3M106-8%N/AN/A
#9
$18.7M93-5%N/AN/A
#10
$17.5M87-1%N/AN/A

Oxford PharmaGenesis is a HealthScience communications consultancy providing services to the healthcare industry, professional societies and patient groups. Founded in 1998, Oxford PharmaGenesis is proud to be an independently owned consultancy in a sector increasingly populated by corporate communications conglomerates. Now employing more than 250 dedicated HealthScience experts in offices in Oxford, London, Philadelphia, Cardiff and Basel, Oxford PharmaGenesis is a preferred supplier to 9 of the top 10 global pharmaceutical companies. Our diverse client list comprises over 50 healthcare organizations, including pharmaceutical, devices, diagnostic and nutraceutical companies, and professional societies, patient groups and academic institutions. Contact us to find out how we apply powerful thinking, dedicated to your success.

keywords:N/A

N/A

Total Funding

532

Number of Employees

$106.9M

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Oxford PharmaGenesis News

2021-08-11 - Plain Language Results of DESTINY-Breast01 Clinical Study: CISCRP & OxfordPharmaGenesis Collaborate with Partners For Article in Future Oncology

The teams involved—Daiichi Sankyo, AstraZeneca, CISCRP, Oxford PharmaGenesis, and Dr. Modi —worked to ensure the PLSP was easy-to-read by adding creative visuals, tables and key questions answered about the DESTINY-Breast01 trial. BOSTON (PRWEB) August 11, 2021 CISCRP (Center for Information a ...

09/03/2019 - Global Tizanidine HCl Market Insights 2019-2026: Actavis ...

... Apotex, Sun Pharmaceutical, CorePharma, Dr. Reddys Laboratories, Mylan, Oxford PharmaGenesis, Niche Generics Limited, Credit Pharma, ...

09/08/2019 - Clinical trial reporting is improved by professional medical ...

The systematic review by researchers at Oxford PharmaGenesis and Ipsen analysed eight studies that included 849 articles written with ...

09/03/2019 - Inebilizumab for the treatment of neuromyelitis optica ...

Ian Williams (Oxford PharmaGenesis, Oxford, UK) was involved in generating and framing the first draft based on input from the authors and ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$217.1M541-1%N/A
#2
$69.5M54512%N/A
#3
$208.2M617N/AN/A
#4
$257.8M625N/AN/A
#5
N/A7753%N/A